Back to Feed
Fintech– 0
Novo Nordisk offers discounted Wegovy subscription
Wsj·
Novo Nordisk is introducing a new subscription program for its Wegovy obesity drugs, aiming to attract customers with a more affordable and predictable monthly cost. This initiative seeks to make the treatment more accessible and competitive in the growing weight-loss drug market. The company's strategy focuses on patient retention and market share expansion by addressing cost barriers associated with long-term medication use.
Tags
product
fintech
Original Source
Wsj — www.wsj.com